L Engelmann1, D V Schmitt. 1. -, Sigebandweg 25, 04279, Leipzig, Deutschland, pdle@gmx.de.
Abstract
BACKGROUND: Appropriate antibiotic initial therapy remarkably decreases the mortality of patients with infections in the ICU. The establishment of an appropriate initial therapy follows empirical aspects. This practice was first done for the treatment of nosocomial pneumonia. Since that time the practice became known as Tarragona strategy. RESULTS: The basic elements of the strategy are based on the initial antibiotic treatment of patients with infections in the ICU in general and include the following: view the patient and his/her medical history, consider the microbiologic environment, in which the patient became ill, test for possible causative microorganisms and initiate high-dose antibiotics immediately, evaluate pharmacokinetic/pharmacodynamic aspects influenced by the pathophysiologic processes in the critically ill patient, the specifics of the microorganisms, the peculiarity of the antibiotics in the patient and due to therapeutic procedures, and tailor the initial broad spectrum therapy as necessary according to the microbiological results. CONCLUSION: This procedure is safe, reduces mortality, limits the development of resistance, and is economic.
BACKGROUND: Appropriate antibiotic initial therapy remarkably decreases the mortality of patients with infections in the ICU. The establishment of an appropriate initial therapy follows empirical aspects. This practice was first done for the treatment of nosocomial pneumonia. Since that time the practice became known as Tarragona strategy. RESULTS: The basic elements of the strategy are based on the initial antibiotic treatment of patients with infections in the ICU in general and include the following: view the patient and his/her medical history, consider the microbiologic environment, in which the patient became ill, test for possible causative microorganisms and initiate high-dose antibiotics immediately, evaluate pharmacokinetic/pharmacodynamic aspects influenced by the pathophysiologic processes in the critically ill patient, the specifics of the microorganisms, the peculiarity of the antibiotics in the patient and due to therapeutic procedures, and tailor the initial broad spectrum therapy as necessary according to the microbiological results. CONCLUSION: This procedure is safe, reduces mortality, limits the development of resistance, and is economic.
Authors: Gordon Choi; Charles D Gomersall; Qi Tian; Gavin M Joynt; Alexander M M Y Li; Jeffrey Lipman Journal: Blood Purif Date: 2010-10-06 Impact factor: 2.614
Authors: Frank M Brunkhorst; Michael Oppert; Gernot Marx; Frank Bloos; Katrin Ludewig; Christian Putensen; Axel Nierhaus; Ulrich Jaschinski; Andreas Meier-Hellmann; Andreas Weyland; Matthias Gründling; Onnen Moerer; Reimer Riessen; Armin Seibel; Maximilian Ragaller; Markus W Büchler; Stefan John; Friedhelm Bach; Claudia Spies; Lorenz Reill; Harald Fritz; Michael Kiehntopf; Evelyn Kuhnt; Holger Bogatsch; Christoph Engel; Markus Loeffler; Marin H Kollef; Konrad Reinhart; Tobias Welte Journal: JAMA Date: 2012-06-13 Impact factor: 56.272
Authors: Frederick Schneider; Christian M Schulz; Matthias May; Gerhard Schneider; Christian Ernst; Matthias Jacob; Kai Zacharowski; Thomas Hachenberg; Maren Schmidt; Moritz Kretzschmar; Bernhard Graf; Martin G Kees; Michael Pawlik; Michael Sander; Christian Koch; Michael Zoller; Markus Heim Journal: BMC Res Notes Date: 2020-03-18